CLO25-097: Randomized Phase II Study of Pembrolizumab 200mg q12 Weeks Versus Standard-of-Care (SOC) Dosing in Stage IV Non-Small Cell Lung Cancer (NSCLC) With Prior Clinical Benefit to Pembrolizumab Monotherapy

Anuja V. Abhyankar; Myung Ju Ahn; Grace K. Dy

doi:10.6004/jnccn.2024.7199

CLO25-097: Randomized Phase II Study of Pembrolizumab 200mg q12 Weeks Versus Standard-of-Care (SOC) Dosing in Stage IV Non-Small Cell Lung Cancer (NSCLC) With Prior Clinical Benefit to Pembrolizumab Monotherapy

Anuja V. Abhyankar
, Myung Ju Ahn
, Grace K. Dy

Department of Internal Medicine

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Original language	English
Journal	JNCCN Journal of the National Comprehensive Cancer Network
Volume	23
Issue number	35
DOIs	https://doi.org/10.6004/jnccn.2024.7199
State	Published - 28 Mar 2025

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.6004/jnccn.2024.7199

Cite this

@article{3f3bcce06ea14f3491f8088b342143d3,

title = "CLO25-097: Randomized Phase II Study of Pembrolizumab 200mg q12 Weeks Versus Standard-of-Care (SOC) Dosing in Stage IV Non-Small Cell Lung Cancer (NSCLC) With Prior Clinical Benefit to Pembrolizumab Monotherapy",

author = "Abhyankar, \{Anuja V.\} and Ahn, \{Myung Ju\} and Dy, \{Grace K.\}",

year = "2025",

month = mar,

day = "28",

doi = "10.6004/jnccn.2024.7199",

language = "English",

volume = "23",

journal = "JNCCN Journal of the National Comprehensive Cancer Network",

issn = "1540-1405",

publisher = "Harborside Press",

number = "35",

}

CLO25-097: Randomized Phase II Study of Pembrolizumab 200mg q12 Weeks Versus Standard-of-Care (SOC) Dosing in Stage IV Non-Small Cell Lung Cancer (NSCLC) With Prior Clinical Benefit to Pembrolizumab Monotherapy. / Abhyankar, Anuja V.; Ahn, Myung Ju; Dy, Grace K.
In: JNCCN Journal of the National Comprehensive Cancer Network, Vol. 23, No. 35, 28.03.2025.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - CLO25-097

T2 - Randomized Phase II Study of Pembrolizumab 200mg q12 Weeks Versus Standard-of-Care (SOC) Dosing in Stage IV Non-Small Cell Lung Cancer (NSCLC) With Prior Clinical Benefit to Pembrolizumab Monotherapy

AU - Abhyankar, Anuja V.

AU - Ahn, Myung Ju

AU - Dy, Grace K.

PY - 2025/3/28

Y1 - 2025/3/28

UR - https://www.scopus.com/pages/publications/105002490500

U2 - 10.6004/jnccn.2024.7199

DO - 10.6004/jnccn.2024.7199

M3 - Article

C2 - 40154362

AN - SCOPUS:105002490500

SN - 1540-1405

VL - 23

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

IS - 35

ER -

CLO25-097: Randomized Phase II Study of Pembrolizumab 200mg q12 Weeks Versus Standard-of-Care (SOC) Dosing in Stage IV Non-Small Cell Lung Cancer (NSCLC) With Prior Clinical Benefit to Pembrolizumab Monotherapy

UN SDGs

Access to Document

Other files and links

Cite this